{"id":"inactivated-vaccine-booster","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine contains inactivated forms of a pathogen, which are unable to cause disease but still trigger an immune response. This response helps the body to recognize and fight off future infections.","oneSentence":"This inactivated vaccine booster works by stimulating the body's immune system to produce a specific response against a particular pathogen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:35:57.727Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT07487077","phase":"PHASE4","title":"Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya","status":"RECRUITING","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2025-10-31","conditions":"Cholera Vaccination","enrollment":1071},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT04127786","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-21","conditions":"Rabies, Healthy Volunteers","enrollment":1708},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT00510497","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cell Vaccine in HIV1 Infection","status":"COMPLETED","sponsor":"Sharon Riddler","startDate":"2007-07","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT05091619","phase":"PHASE3","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2021-10-22","conditions":"Whooping Cough, Diphtheria, Tetanus","enrollment":2898},{"nctId":"NCT04300192","phase":"PHASE4","title":"Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-01-27","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":273},{"nctId":"NCT05077137","phase":"PHASE1","title":"A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy","status":"RECRUITING","sponsor":"Duke University","startDate":"2021-09-07","conditions":"Melanoma","enrollment":25},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05716347","phase":"EARLY_PHASE1","title":"Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2022-07-13","conditions":"COVID-19","enrollment":80},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT05727215","phase":"PHASE2","title":"Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2023-02-28","conditions":"COVID-19","enrollment":150},{"nctId":"NCT05525208","phase":"PHASE2","title":"Booster Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-09-01","conditions":"COVID-19","enrollment":696},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT05465902","phase":"PHASE2","title":"Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster","status":"WITHDRAWN","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2023-07-07","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT05204589","phase":"PHASE3","title":"Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-01-22","conditions":"COVID-19","enrollment":10285},{"nctId":"NCT05303584","phase":"PHASE4","title":"Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-04-23","conditions":"COVID-19","enrollment":362},{"nctId":"NCT05354024","phase":"PHASE2, PHASE3","title":"Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-02-28","conditions":"Coronavirus Infections, Healthy","enrollment":4400},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT05874713","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-07","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":480},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT05574985","phase":"NA","title":"Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-08-29","conditions":"COVID-19","enrollment":272},{"nctId":"NCT05463419","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.","status":"COMPLETED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2022-10-03","conditions":"Covid-19 Vaccine","enrollment":5860},{"nctId":"NCT06460545","phase":"PHASE4","title":"Phase IV Study of Concomitant Administration of the sIPV and HepA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-06-15","conditions":"Polio, Hepatitis A","enrollment":2000},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":"COVID-19","enrollment":1750},{"nctId":"NCT05863429","phase":"","title":"Observational National Vaccine Study","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-05-18","conditions":"COVID-19 Infection","enrollment":200},{"nctId":"NCT06381843","phase":"NA","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2022-08-02","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":120},{"nctId":"NCT05463354","phase":"PHASE2","title":"Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2022-07-11","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":410},{"nctId":"NCT05386810","phase":"PHASE3","title":"Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-11-05","conditions":"Poliomyelitis","enrollment":1572},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT06091410","phase":"PHASE4","title":"Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Catholic Kwandong University","startDate":"2023-09-25","conditions":"COVID-19, Influenza, Vaccine Reaction","enrollment":62},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05077176","phase":"PHASE3","title":"Phase 3 Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-10-08","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":4340},{"nctId":"NCT05981846","phase":"PHASE2","title":"A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-09-04","conditions":"SARS CoV 2 Infection, Influenza, Human","enrollment":279},{"nctId":"NCT06272253","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-09-19","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":250},{"nctId":"NCT06259578","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2024-01-29","conditions":"COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease","enrollment":400},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT05343871","phase":"PHASE4","title":"Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2022-07-05","conditions":"COVID-19","enrollment":2354},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06208683","phase":"PHASE4","title":"The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-11-04","conditions":"Mumps, Influenza","enrollment":400},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT04979949","phase":"PHASE2","title":"Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-07-12","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":222},{"nctId":"NCT05329038","phase":"PHASE4","title":"Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2022-04-19","conditions":"COVID-19","enrollment":180},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT04220515","phase":"PHASE4","title":"Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-02-08","conditions":"Poliomyelitis","enrollment":49731},{"nctId":"NCT05683600","phase":"PHASE3","title":"Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older","status":"TERMINATED","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-12-29","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT05664932","phase":"PHASE3","title":"Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-12-28","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT05254236","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-02-10","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05411471","phase":"PHASE2","title":"Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain","status":"COMPLETED","sponsor":"Sinovac Biotech (Hong Kong) Limited","startDate":"2022-06-08","conditions":"COVID-19","enrollment":221},{"nctId":"NCT05205096","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-11-10","conditions":"COVID-19","enrollment":480},{"nctId":"NCT04956224","phase":"PHASE3","title":"Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-08-09","conditions":"SARS-CoV-2 Virus Infection","enrollment":306},{"nctId":"NCT05422326","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-07-18","conditions":"Influenza, Human, Influenza in Birds, Respiratory Tract Infections","enrollment":260},{"nctId":"NCT05609045","phase":"PHASE1","title":"A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster","status":"WITHDRAWN","sponsor":"Wuhan Rhegen Biotechnology Co., Ltd.","startDate":"2023-06","conditions":"COVID-19 Pandemic","enrollment":""},{"nctId":"NCT05928455","phase":"EARLY_PHASE1","title":"The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-05-14","conditions":"COVID-19, Vaccine Reaction","enrollment":120},{"nctId":"NCT05928468","phase":"EARLY_PHASE1","title":"The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2023-04-25","conditions":"COVID-19","enrollment":210},{"nctId":"NCT05082688","phase":"PHASE2","title":"Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-09-20","conditions":"Influenza, Herpes Zoster","enrollment":148},{"nctId":"NCT05918939","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":350},{"nctId":"NCT04510207","phase":"PHASE3","title":"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-07-16","conditions":"COVID-19","enrollment":44101},{"nctId":"NCT04917523","phase":"PHASE3","title":"Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-07-02","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":1800},{"nctId":"NCT05895110","phase":"NA","title":"To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2022-04-29","conditions":"COVID-19","enrollment":240},{"nctId":"NCT05364242","phase":"PHASE2, PHASE3","title":"VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2022-05-09","conditions":"SARS-CoV-2 Infection","enrollment":178},{"nctId":"NCT05323435","phase":"PHASE2","title":"Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)","status":"COMPLETED","sponsor":"Jiangsu Rec-Biotechnology Co., Ltd.","startDate":"2022-05-30","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05096832","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-03","conditions":"COVID-19 Pandemic","enrollment":10381},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT05330871","phase":"PHASE2","title":"Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.","status":"UNKNOWN","sponsor":"Seventh Medical Center of PLA General Hospital","startDate":"2022-04-17","conditions":"COVID-19","enrollment":410},{"nctId":"NCT05580159","phase":"PHASE3","title":"New Generation mRNA Booster Vaccine Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10","conditions":"Immunogenicity, Efficacy, Safety","enrollment":2000},{"nctId":"NCT05323461","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2022-05-30","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":1800},{"nctId":"NCT03669627","phase":"PHASE2","title":"CT18 Infant Influenza Priming Study in Vaccine Naive Infants","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-11-01","conditions":"Influenza","enrollment":159},{"nctId":"NCT04864561","phase":"PHASE3","title":"COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2021-04-26","conditions":"SARS-CoV-2 Virus Infection","enrollment":4034},{"nctId":"NCT05545683","phase":"PHASE3","title":"Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination","status":"WITHDRAWN","sponsor":"Centro de Estudios en Infectogía Pediatrica","startDate":"2022-12-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05156632","phase":"PHASE3","title":"Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2023-02-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05428592","phase":"PHASE3","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":1100},{"nctId":"NCT05686161","phase":"PHASE3","title":"mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs","status":"UNKNOWN","sponsor":"Stemirna Therapeutics","startDate":"2022-10-19","conditions":"Immunogenicity, Safety, Efficacy","enrollment":600},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05433272","phase":"PHASE3","title":"Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated","status":"UNKNOWN","sponsor":"Sinovac Biotech (Colombia) S.A.S.","startDate":"2023-08-10","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT05305300","phase":"PHASE1","title":"A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals","status":"COMPLETED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2021-10-18","conditions":"COVID-19 Pandemic","enrollment":135},{"nctId":"NCT04817917","phase":"PHASE4","title":"Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-03-01","conditions":"Japanese Encephalitis, Vaccine Preventable Disease, Vaccine Reaction","enrollment":712},{"nctId":"NCT05585567","phase":"EARLY_PHASE1","title":"A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2022-09-16","conditions":"COVID-19 Pandemic","enrollment":48},{"nctId":"NCT05602558","phase":"PHASE2, PHASE3","title":"The Phase Ⅱ/Ⅲ Trial of LYB001","status":"UNKNOWN","sponsor":"Yantai Patronus Biotech Co., Ltd.","startDate":"2022-12","conditions":"COVID-19","enrollment":18000},{"nctId":"NCT05583357","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2022-08-15","conditions":"COVID-19 Pandemic","enrollment":40},{"nctId":"NCT05492643","phase":"NA","title":"The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2022-08-13","conditions":"SARS-CoV-2, Safety, Immunotoxicity","enrollment":1000},{"nctId":"NCT05547802","phase":"","title":"Serology After BBIBP-CorV Inactivated Vaccine Combined With BNT62b2 mRNA Booster Vaccine","status":"COMPLETED","sponsor":"University of Debrecen","startDate":"2021-11-16","conditions":"Basic BBIBP-CorV Vaccination is Not as Effective as BNT162b","enrollment":122},{"nctId":"NCT05109559","phase":"PHASE1, PHASE2","title":"Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-12-20","conditions":"SARS-CoV-2 Infection","enrollment":690},{"nctId":"NCT05172193","phase":"PHASE2","title":"Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)","status":"UNKNOWN","sponsor":"PT. Kimia Farma (Persero) Tbk","startDate":"2021-12-31","conditions":"COVID-19","enrollment":600},{"nctId":"NCT04952727","phase":"PHASE4","title":"Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-08-26","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT05165966","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-10-20","conditions":"COVID-19","enrollment":340},{"nctId":"NCT04383574","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2020-05-22","conditions":"COVID-19","enrollment":422},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT05165732","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-20","conditions":"COVID-19","enrollment":480},{"nctId":"NCT05493917","phase":"","title":"A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-11-03","conditions":"COVID-19, Vaccine Reaction","enrollment":2000},{"nctId":"NCT04671017","phase":"PHASE1, PHASE2","title":"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2020-12-16","conditions":"SARS-CoV-2 Virus Infection","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CoronaVac"],"phase":"phase_2","status":"active","brandName":"Inactivated vaccine booster","genericName":"Inactivated vaccine booster","companyName":"Universidad del Desarrollo","companyId":"universidad-del-desarrollo","modality":"Biologic","firstApprovalDate":"","aiSummary":"This inactivated vaccine booster works by stimulating the body's immune system to produce a specific response against a particular pathogen. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}